Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe
Year: 2024
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: Real-world data evaluating how approvals of novel treatment regimens for ovarian cancer have impacted the treatment paradigm, including first-line maintenance, are lacking. This analysis aimed to describe treatment patterns for advanced epithelial ovarian cancer in Europe and the USA in the first-line maintenance setting. Patient characteristics, biomarker testing rates, and drivers of treatment choice were also evaluated. METHODS: A retrospective chart review study of electronic medical records in Europe and the USA was conducted for patients diagnosed with epithelial ovarian cancer (June 1, 2017-May 31, 2020), in line with Healthcare Market Research guidelines. Eligible physicians extracted data from electronic medical records by completing standardized patient record forms, including questions on patient involvement in treatment decisions. Patients with advanced (stage III/IV) disease were stratified by country and diagnosis date to provide information on treatment patterns. RESULTS: mutations or homologous recombination deficiency increased. Patient preference was documented as a reason for treatment selection in approximately one-sixth of cases in the first-line adjuvant and first-line maintenance settings. The use of first-line maintenance poly(ADP-ribose) polymerase inhibitor monotherapy increased over time, while the use of vascular endothelial growth factor inhibitor monotherapy decreased. CONCLUSIONS: This real-world study showed that treatment patterns for advanced epithelial ovarian cancer varied by country. Rates of physician-reported patient involvement in treatment decisions in the first-line adjuvant and maintenance treatment settings for ovarian cancer were low, highlighting an unmet need for initiatives to improve patient involvement in shared decision-making regarding maintenance therapy selection.
Institutions: OU Health Stephenson Cancer Center, University of Oklahoma, Copenhagen University Hospital, Rigshospitalet, Nordic Society of Gynecologic Oncology, Edinburgh Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Humanitas University, Gynecologic Oncology Group, Florida Cancer Specialists & Research Institute, Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie, Charité - Universitätsmedizin Berlin, GlaxoSmithKline (United States), Clinica Universidad de Navarra, Spanish Ovarian Cancer Research Group, Centro de Investigación Médica Aplicada
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,800
OpenAlex ID: W4401728514